Table of Contents
Lung Cancer International
Volume 2017 (2017), Article ID 9614938, 5 pages
https://doi.org/10.1155/2017/9614938
Research Article

Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma

1Velindre Cancer Centre, Cardiff, UK
2Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK
3University Hospital Llandough, Cardiff, UK

Correspondence should be addressed to Rhian Siân Davies

Received 9 November 2016; Revised 16 February 2017; Accepted 20 February 2017; Published 7 March 2017

Academic Editor: Giovanni Luca Ceresoli

Copyright © 2017 Rhian Siân Davies et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives. There have been advances in the identification and understanding of molecular subsets of lung cancer, defined by specific oncogenic aberrations. A number of actionable genetic alterations have been identified, such as the epidermal growth factor receptor (EGFR) mutation. We aimed to establish the reasons why patients were not undergoing EGFR mutation testing at the time of histological diagnosis. Methods. The records of 70 patients with advanced adenocarcinoma of the lung managed through a single multidisciplinary team at a single institution were reviewed. Data were collected on method of tumour sample collection, whether this was sent for EGFR testing, and the result. Results. Seventy patients were identified. In 21/25 (84%) cases, cytological sampling was sufficient for EGFR mutation analysis, compared with 40/45 (89%) cases with histological sampling. EGFR mutation testing was not carried out in 22/70 (31.4%) patients. There was insufficient tumour sample for EGFR testing in 9/22 (40.9%) patients. Other reasons for not testing included poor patient fitness and problems in the diagnostic pathway. Conclusions. In this series, cytological tumour sampling was not the predominant reason why cancers failed to have EGFR mutation status established.